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Agnes I VitryWe thank Michael Wonder for his comments on our
article ‘Assessment of the therapeutic value of new medi-
cines marketed in Australia’ which give us the opportun-
ity to clarify some points further. We agree with him
that the definition of pharmaceutical products which are
‘considered innovative as long as they are new and the
success of innovation is defined in terms of sales, with the
assumption that higher sales is a measure of the intrinsic
worth of the innovation’ is more befitting of a pharma-
ceutical industry perspective than a standard definition
used in economics. However, the confusion between
‘new’ and ‘innovative’ is often fostered in economic re-
ports where ‘the conventional benchmark for measuring
the pace of pharmaceutical innovation has been the total
number of new molecular entities’ approved each year’
[1]. Therefore, the main aim of our study was to demon-
strate that ‘new’ was not equivalent to ‘innovative’ with
regards to therapeutic value in the context of pervasive
beliefs that all new medicines bring ‘therapeutic
innovation and better health outcomes’. Wonder states
that we did not present solid evidence that such beliefs
are widespread in Australia. Although we have not been
able to identify a recent survey on this topic in Australia,
there is evidence of these beliefs in other countries. In a
recent US study, 39% of participants mistakenly believed
that the US FDA approves only "extremely effective"
drugs; 25% mistakenly believed that the FDA approves
only drugs without serious side effects [2]. There is no
evidence that the Australian public is more aware than
the American public that only a minority of the new
medicines marketed every year provides added the-
rapeutic value compared to existing treatments. These
beliefs are strongly encouraged by the pharmaceuticalCorrespondence: agnes.vitry@unisa.edu.au
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Wonder comments that we are ‘rather vague’ on what
comparisons should be made to determine the thera-
peutic value of a medicine. The valuation of therapeutic
innovation has mainly been addressed by funding agen-
cies such as the Pharmaceutical Benefits Scheme (PBS)
in Australia that requires evidence for efficacy, safety
and cost-effectiveness of a new medicine against an ap-
propriate comparator. Medicine regulatory agencies such
as the Therapeutics Goods Administration (TGA) typic-
ally require the demonstration of the efficacy of a medi-
cine against a placebo. The two main sources of
information we used in our study to inform our assess-
ment of the therapeutic value of new medicines were the
French independent medical journal Prescrire, and the
Pharmaceutical Benefits Advisory Committee (PBAC)’s
assessments. Both use the best standard of current care
as the comparator to estimate the therapeutic value of
new medicines.
Wonder comments that we seem to imply that the
TGA should only register new medicines that are associ-
ated with a clear benefit and that this may lead to only
one registered medicine in a given pharmacological
class. This is not our point. We argued that the TGA
and other regulatory agencies should only register medi-
cines that have been shown to be equally effective and
safe as previously registered medicines. The current ap-
proval system allows the registration of medicines that
may be less effective or less safe than existing medicines
but may be heavily promoted as ‘newer’ and explicitly or
implicitly ‘better’ medicines.
Wonder states that there is ample local experience to
indicate that payers do not pay more for new medicines
that do not provide any additional therapeutic benefit.
We acknowledge that the PBAC does its best to get
good value for money for new medicines despite the
strong criticisms of the industry. However, there are alsos is an open access article distributed under the terms of the Creative Commons
rg/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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medicines (e.g. atorvastatin) compared to other coun-
tries that choose to promote and fund the use of older,
off-patent medicines such as simvastatin.
Wonder comments that we ‘do not cite any examples
where the safety of the Australian public has been
compromised as a result of supposedly lax approval cri-
teria’. In Australia, we are fortunate to have a strong
funding agency, the PBS, that imposes restrictions on
use of new medicines to ensure that they are used in a
safe and cost-effective manner. However, PBS restric-
tions may not always be implemented in practice and
there are numerous examples of ‘leakage’, i.e. use of
medicines by health professionals outside the PBS re-
stricted indications, often as a result of intensive mar-
keting campaigns. For example, a large proportion of
prescriptions supplied through the PBS for the ‘gliptins’,
a new class of diabetes drugs do not currently meet the
criteria for PBS subsidy [3]. These medicines have not
demonstrated benefits in terms of long-term health
outcomes compared to older diabetes medicines and
have raised serious safety concerns. The extensive use
of these diabetes medicines may expose Australian pa-
tients to serious adverse effects without additional
therapeutic benefit.
Finally, Wonder asks us to provide details on how
stricter regulatory approval criteria would simplify the re-
imbursement process. Demands have be made for a
strengthening of the criteria for regulatory approval in-
cluding the requirement to demonstrate a minimal thera-
peutic improvement, in particular for cancer drugs [4,5],
and requirement of active-controlled trials [6,7] that
would therefore facilitate the assessment of the thera-
peutic value of new medicines by funding agencies [6-8].Competing interests
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